Charles Grob M.D.
Dr. Grob is currently Professor of Psychiatry and Pediatrics at the UCLA School of Medicine and the Director of the Division of Child and Adolescent Psychiatry at the Harbor-UCLA Medical Center. Dr. Grob is co-founder and director of Clinical Research of the Heffter Research Institute.
He has a long-standing interest in the history of psychiatric research with hallucinogens, and has published in the psychiatric literature and has given talks at professional meetings in this area. Dr. Grob received the first FDA approval to carry out human research with 3,4-methylenedioxymethamphetamine (MDMA).
He collaborated with Drs. Dennis McKenna and Jace Callaway on a project to study the biochemical, physiological, and psychological parameters of long-term ayahuasca use in Brazil. In collaboration with Dr. Marlene Dobkin de Rios, he has examined the sociocultural context within which the use of these compounds occurs.
In 2004 Dr. Grob initiated an FDA approved research investigation examining the effects of psilocybin in advanced-stage cancer patients with severe anxiety, which was completed in 2008. He is also the editor of Hallucinogens: A Reader, and the co-editor with Dr. Roger Walsh of Higher Wisdom: Eminent Elders Explore the Continuing Impact of Psychedelics.
Dr. Grob talks about how he began his career in psychedelics research and his Psilocybin at the End of Life study